Literature DB >> 19470762

Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.

Sunil Sudarshan1, Carole Sourbier, Hye-Sik Kong, Karen Block, Vladimir A Valera Romero, Youfeng Yang, Cynthia Galindo, Mehdi Mollapour, Bradley Scroggins, Norman Goode, Min-Jung Lee, Campbell W Gourlay, Jane Trepel, W Marston Linehan, Len Neckers.   

Abstract

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an inherited cancer syndrome linked to biallelic inactivation of the gene encoding the tricarboxylic acid cycle enzyme fumarate hydratase (FH). Individuals with HLRCC are at risk to develop cutaneous and uterine leiomyomas and an aggressive form of kidney cancer. Pseudohypoxic drive-the aberrant activation of cellular hypoxia response pathways despite normal oxygen tension-is considered to be a likely mechanism underlying the etiology of this tumor. Pseudohypoxia requires the oxygen-independent stabilization of the alpha subunit of the hypoxia-inducible transcription factor (HIF-1alpha). Under normoxic conditions, proline hydroxylation of HIF-1alpha permits VHL recognition and subsequent targeting for proteasomal degradation. Here, we demonstrate that inactivating mutations of FH in an HLRCC-derived cell line result in glucose-mediated generation of cellular reactive oxygen species (ROS) and ROS-dependent HIF-1alpha stabilization. Additionally, we demonstrate that stable knockdown of FH in immortalized renal epithelial cells results in ROS-dependent HIF-1alpha stabilization. These data reveal that the obligate glycolytic switch present in HLRCC is critical to HIF stabilization via ROS generation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470762      PMCID: PMC2715796          DOI: 10.1128/MCB.00483-09

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

Authors:  M S Wiesener; P M Münchenhagen; I Berger; N V Morgan; J Roigas; A Schwiertz; J S Jürgensen; G Gruber; P H Maxwell; S A Löning; U Frei; E R Maher; H J Gröne; K U Eckardt
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

2.  High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers.

Authors:  S Walenta; M Wetterling; M Lehrke; G Schwickert; K Sundfør; E K Rofstad; W Mueller-Klieser
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  Inherited susceptibility to uterine leiomyomas and renal cell cancer.

Authors:  V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

4.  NAD(P)H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells.

Authors:  Hyun Seung Lee; Seok Man Son; Yong Ki Kim; Ki Whan Hong; Chi Dae Kim
Journal:  Life Sci       Date:  2003-05-02       Impact factor: 5.037

5.  A conserved family of prolyl-4-hydroxylases that modify HIF.

Authors:  R K Bruick; S L McKnight
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

6.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Authors:  A C Epstein; J M Gleadle; L A McNeill; K S Hewitson; J O'Rourke; D R Mole; M Mukherji; E Metzen; M I Wilson; A Dhanda; Y M Tian; N Masson; D L Hamilton; P Jaakkola; R Barstead; J Hodgkin; P H Maxwell; C W Pugh; C J Schofield; P J Ratcliffe
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

7.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

8.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

9.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.

Authors:  Ian P M Tomlinson; N Afrina Alam; Andrew J Rowan; Ella Barclay; Emma E M Jaeger; David Kelsell; Irene Leigh; Patricia Gorman; Hanan Lamlum; Shamima Rahman; Rebecca R Roylance; Simon Olpin; Stephen Bevan; Karen Barker; Nicholas Hearle; Richard S Houlston; Maija Kiuru; Rainer Lehtonen; Auli Karhu; Susa Vilkki; Päivi Laiho; Carita Eklund; Outi Vierimaa; Kristiina Aittomäki; Marja Hietala; Pertti Sistonen; Anders Paetau; Reijo Salovaara; Riitta Herva; Virpi Launonen; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2002-02-25       Impact factor: 38.330

10.  A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death.

Authors:  Tabitha E Wood; Shadi Dalili; Craig D Simpson; Rose Hurren; Xinliang Mao; Fernando Suarez Saiz; Marcela Gronda; Yanina Eberhard; Mark D Minden; Philip J Bilan; Amira Klip; Robert A Batey; Aaron D Schimmer
Journal:  Mol Cancer Ther       Date:  2008-11       Impact factor: 6.261

View more
  112 in total

1.  Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.

Authors:  Chunxiao Wu; Alexander W Wyatt; Anna V Lapuk; Andrew McPherson; Brian J McConeghy; Robert H Bell; Shawn Anderson; Anne Haegert; Sonal Brahmbhatt; Robert Shukin; Fan Mo; Estelle Li; Ladan Fazli; Antonio Hurtado-Coll; Edward C Jones; Yaron S Butterfield; Faraz Hach; Fereydoun Hormozdiari; Iman Hajirasouliha; Paul C Boutros; Robert G Bristow; Steven Jm Jones; Martin Hirst; Marco A Marra; Christopher A Maher; Arul M Chinnaiyan; S Cenk Sahinalp; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

Review 2.  Cellular metabolism and disease: what do metabolic outliers teach us?

Authors:  Ralph J DeBerardinis; Craig B Thompson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

3.  Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism.

Authors:  Chiara Bardella; Martina Olivero; Annalisa Lorenzato; Massimo Geuna; Julie Adam; Linda O'Flaherty; Pierre Rustin; Ian Tomlinson; Patrick J Pollard; Maria Flavia Di Renzo
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 4.  Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets.

Authors:  Jamie D Weyandt; Craig B Thompson; Amato J Giaccia; W Kimryn Rathmell
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 5.  Precision medicine from the renal cancer genome.

Authors:  Yasser Riazalhosseini; Mark Lathrop
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

6.  In vitro ischemia suppresses hypoxic induction of hypoxia-inducible factor-1α by inhibition of synthesis and not enhanced degradation.

Authors:  Saravanan S Karuppagounder; Manuela Basso; Sama F Sleiman; Thong C Ma; Rachel E Speer; Natalya A Smirnova; Irina G Gazaryan; Rajiv R Ratan
Journal:  J Neurosci Res       Date:  2013-03-04       Impact factor: 4.164

7.  Photoinducible Oncometabolite Detection.

Authors:  Rhushikesh A Kulkarni; Chloe A Briney; Daniel R Crooks; Sarah E Bergholtz; Chandrasekhar Mushti; Stephen J Lockett; Andrew N Lane; Teresa W-M Fan; Rolf E Swenson; W Marston Linehan; Jordan L Meier
Journal:  Chembiochem       Date:  2018-12-13       Impact factor: 3.164

8.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.

Authors:  Youfeng Yang; Vladimir A Valera; Hesed M Padilla-Nash; Carole Sourbier; Cathy D Vocke; Manish A Vira; Mones S Abu-Asab; Gennady Bratslavsky; Maria Tsokos; Maria J Merino; Peter A Pinto; Ramaprasad Srinivasan; Thomas Ried; Len Neckers; W Marston Linehan
Journal:  Cancer Genet Cytogenet       Date:  2010-01-01

Review 9.  Molecular diagnosis and therapy of kidney cancer.

Authors:  W Marston Linehan; Gennady Bratslavsky; Peter A Pinto; Laura S Schmidt; Len Neckers; Donald P Bottaro; Ramaprasad Srinivasan
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

Review 10.  Metabolism of kidney cancer: from the lab to clinical practice.

Authors:  Sunil Sudarshan; Jose A Karam; James Brugarolas; R Houston Thompson; Robert Uzzo; Brian Rini; Vitaly Margulis; Jean-Jacques Patard; Bernard Escudier; W Marston Linehan
Journal:  Eur Urol       Date:  2012-09-28       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.